PAK1 mediates resistance to PI3K inhibition in lymphomas

Clinical Cancer Research

Volumn 19, Issue 5, 2013, Pages 1106-1115

  Walsh, Katherine ^a,b   McKinney, Matthew S ^a,b   Love, Cassandra ^a   Liu, Qingquan ^a   Fan, Alice ^a   Patel, Amee ^a   Smith, Jason ^a,b   Beaven, Anne ^b   Jima, Dereje D ^a   Dave, Sandeep S ^a,b  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BGT 226; BUPARLISIB; P21 ACTIVATED KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; GERM CELL TUMOR; HODGKIN DISEASE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; T CELL LYMPHOMA; WESTERN BLOTTING;

AMINOPYRIDINES; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; HUMANS; IMIDAZOLES; LYMPHOMA; MORPHOLINES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P21-ACTIVATED KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84874925474     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1060     Document Type: Article

References (30)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107: 265-76.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon France: IARC Press; 2008.
3. Dave SS, Fu K, WrightGW,LamLT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt's lymphoma. N Eng J Med 2006;354: 2431-42.
4. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TH, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Eng J Med 2006;354: 2419-30.
5. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403: 503-11.
6. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105: 1851-61.
7. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005;106: 3183-90.
8. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev 2002;2: 489-501.
9. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8: 627-44.
10. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68: 8022-30.
11. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28: 1075-83.
12. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010;24: 1781-4.
13. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 2011;17: 2373-84.
14. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010;16: 5424-35.
15. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010;115: 559-69.
16. Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, et al. CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med 2011;3: 74ra22.
17. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, ChoiWW,et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010;116:e118-127.
18. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci US A 1998;95: 14863-8.
19. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008;15: 322-31.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22: 27-55.
21. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Eng J Med 2004;351: 2159-69.
22. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S, et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 2000;1: 419-25.
23. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol- 3 kinase. J Biol Chem 1998;273: 28238-46.
24. Kamai T, Shirataki H, Nakanishi K, Furuya N, Kambara T, Abe H, et al. Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. BMC Cancer 2010; 10: 164.
25. Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A 2011;108: 7177-82.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102: 15545-50.
27. Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009;28: 51-63.
28. Strochlic TI, Viaud J, Rennefahrt UE, Anastassiadis T, Peterson Jr. Phosphoinositides are essential coactivators for p21-activated kinase 1. Mol Cell 2010;40: 493-500.
29. Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, Tam KF, et al. Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. Int J Cancer 2010;127: 21-31.
30. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006;98: 671-80.